Panic Disorder Market: Size, Share, Trends, Growth, and Key Players (2025–2034)

Overview of the Panic Disorder Market

The panic disorder market is steadily gaining global recognition due to the increasing emphasis on improving mental health and the growing prevalence of anxiety-related conditions. Panic disorder is a type of anxiety disorder characterized by recurring panic attacks involving sudden episodes of intense fear or discomfort, often accompanied by physical symptoms such as rapid heartbeat, chest pain, dizziness, or shortness of breath.

As awareness about mental health continues to improve and more individuals seek medical intervention, the demand for effective treatment options is rising. This includes pharmacological therapies, such as antidepressants and anti-anxiety medications, as well as non-pharmacological approaches like cognitive-behavioral therapy (CBT).

In 2024, the panic disorder market size in the 7 major markets (7MM) was valued at USD 9.70 billion. With a growing focus on improving mental well-being, expanding healthcare access, and ongoing pharmaceutical innovation, the market is projected to grow at a CAGR of 4.18% from 2025 to 2034, reaching a value of USD 14.61 billion by 2034.

Size and Share of the Panic Disorder Market

Market Size

• 2024 Market Value: USD 9.70 Billion

• 2034 Projected Value: USD 14.61 Billion

• CAGR (2025–2034): 4.18%

Market Share by Region

• North America: Dominates the market, driven by high prevalence of panic disorder, awareness campaigns, advanced healthcare infrastructure, and strong pharmaceutical presence.

• Europe: Holds a substantial share due to rising government funding for mental health programs and growing diagnosis rates.

• Asia-Pacific: Expected to grow significantly due to increasing acceptance of mental health treatments, improved healthcare systems, and stigma reduction efforts.

• Latin America & Middle East: Emerging markets with increasing adoption of mental health treatments but still hampered by limited awareness and infrastructure challenges.

Market Share by Treatment

• Pharmacological Therapies:

  • SSRIs (Selective Serotonin Reuptake Inhibitors): Commonly prescribed first-line treatment.

  • SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Used for patients with SSRI resistance.

  • Benzodiazepines: Effective for short-term management but limited by addiction risks.

• Non-Pharmacological Therapies:

  • Cognitive Behavioral Therapy (CBT) remains one of the most effective interventions.

  • Lifestyle Interventions & Support Programs complement drug-based therapies.

Market Dynamics and Trends

Market Drivers

• Increasing Mental Health Awareness: Growing global initiatives are encouraging individuals to seek professional help.

• Technological Advancements in Telepsychiatry: Digital platforms are expanding access to panic disorder treatment.

• Strong Pharmaceutical Pipeline: Ongoing R&D for novel anxiolytics and antidepressants is boosting market expansion.

• Supportive Government Policies: Mental health is increasingly becoming a healthcare priority in several countries.

Market Restraints

• Social Stigma Around Mental Health: Still prevalent in certain regions, limiting treatment adoption.

• Side Effects of Medications: SSRIs, SNRIs, and benzodiazepines can cause significant adverse effects.

• High Relapse Rates: Many patients discontinue treatment prematurely, leading to recurring panic attacks.

Emerging Trends

• Personalized Medicine: Tailoring therapies based on genetic and biomarker data.

• Digital Cognitive Behavioral Therapy (dCBT): Online CBT platforms are gaining traction.

• Integration of AI in Diagnosis: AI-powered tools are helping in early detection and monitoring of panic disorder.

• Combination Therapies: Increasing adoption of pharmacological and behavioral therapies together for improved outcomes.

Read full report: https://www.expertmarketresearch.com/reports/panic-disorder-market/requestsample

Growth Outlook of the Panic Disorder Market

The panic disorder market is projected to show moderate but steady growth during the forecast period. Key factors driving growth include:

• Increased Investments in R&D: Major pharmaceutical companies are investing heavily in developing safer and more effective anxiolytics.

• Growing Healthcare Expenditure: Both developed and emerging nations are expanding healthcare budgets for mental health.

• Expanding Telemedicine Adoption: Post-pandemic, telehealth has become a viable treatment delivery channel.

• Patient-Centric Treatment Models: Focus on quality of life improvements beyond just symptom management.

By 2034, the market is anticipated to reach USD 14.61 billion, reflecting the importance of mental health solutions globally.

Market Opportunities and Challenges

Opportunities

• Unmet Medical Need: Existing therapies do not fully address relapse and side effects, offering room for innovation.

• Emerging Markets: Expanding healthcare access in Asia-Pacific and Latin America.

• Biologics & Novel Therapies: Growing potential for biologics and neurostimulation treatments.

• Digital Health Integration: AI-driven apps and wearable technologies for panic disorder monitoring.

Challenges

• Treatment Adherence Issues: Long treatment durations discourage consistent patient participation.

• Patent Expiries of Major Drugs: Generic competition can affect revenue growth.

• Complex Diagnosis: Panic disorder often overlaps with other psychiatric conditions, making diagnosis challenging.

• Limited Awareness in Low-Income Regions: Stigma and lack of resources hinder adoption.

Recent Developments in the Panic Disorder Market

• Pipeline Therapies: Several novel drugs are in Phase II and Phase III trials targeting panic and anxiety disorders.

• Digital CBT Platforms: Growing acceptance of online mental health platforms in North America and Europe.

• Collaborations & Acquisitions: Pharma companies are partnering with digital health startups to enhance mental health care delivery.

• Regulatory Approvals: Increased FDA and EMA approvals for antidepressants with expanded indications.

• Wearable Mental Health Devices: Devices tracking stress levels are being integrated into therapy programs.

Competitor Analysis

The panic disorder market is moderately competitive, with global pharmaceutical giants and mental health innovators leading developments.

Key Players in the Panic Disorder Market

• Teva Pharmaceutical Industries Ltd – Offers a broad portfolio of generic drugs, including treatments for panic disorder.

• Sun Pharmaceutical Industries Ltd. – Expanding into central nervous system (CNS) drugs with strong generic offerings.

• Mylan – Known for affordable generic formulations, improving accessibility to panic disorder therapies.

• AstraZeneca – Invested in neuroscience and anxiety-related R&D.

• Abbott – Active in mental health drug development and diagnostics.

• Baxter – Provides supportive solutions in healthcare infrastructure.

• Bristol-Myers Squibb Company – Developing novel psychiatric treatments with strong CNS pipeline.

• Eli Lilly and Company – Known for its antidepressant portfolio, including SSRIs and SNRIs.

• F. Hoffmann-La Roche Ltd – Investing in psychiatric research and biomarker-driven therapies.

• GlaxoSmithKline plc – Strong global presence in antidepressants and anxiety medications.

• Recordati S.p.A. – Focused on niche therapies including CNS disorders.

• Boehringer Ingelheim International GmbH. – Developing innovative drugs targeting psychiatric conditions.

• Neurocrine Biosciences, Inc. – Specializes in neurological and psychiatric therapies.

• Sanofi – Strong pipeline and presence in CNS therapeutic development.

These players compete through drug innovation, partnerships, and expanding market reach across developed and emerging economies.

Market Growth Projection

The panic disorder market is expected to maintain steady momentum throughout 2025–2034.

• 2034 Value Projection: USD 14.61 Billion

• Growth Rate: CAGR of 4.18%

• Key Drivers: Rising awareness, digital health adoption, pharmaceutical innovations, and expansion into emerging markets.

Frequently Asked Questions (FAQs)

What is the current market size of the panic disorder market?
The panic disorder market was valued at USD 9.70 billion in 2024 across the 7 major markets.

What is the projected growth of the panic disorder market?
The market is expected to reach USD 14.61 billion by 2034, growing at a CAGR of 4.18%.

What factors are driving the panic disorder market growth?
Key drivers include growing awareness of mental health, technological advancements in telemedicine, and pharmaceutical innovations.

Which regions dominate the panic disorder market?
North America leads the market, followed by Europe, while Asia-Pacific is expected to record the fastest growth.

Who are the major players in the panic disorder market?
Leading companies include Teva, Sun Pharma, Mylan, AstraZeneca, Abbott, Baxter, Eli Lilly, Roche, GSK, Sanofi, and Neurocrine Biosciences.

What challenges does the panic disorder market face?
Challenges include treatment adherence issues, stigma in emerging markets, side effects of current drugs, and high relapse rates.

Find More Report:

CDMO Market: https://bit.ly/45yUr3r

Dementia Drugs Market: https://bit.ly/3IXwPwz

Liver Fibrosis Market: https://bit.ly/3TOmC87